Technical Resources &
Thought Leadership

This poster presents Veloxity’s LC–MS/MS methods for quantifying semaglutide and tirzepatide in plasma and brain tissue. Explore data demonstrating low-ng/mL sensitivity, reproducible quantitation and reliable performance across matrices.

See how Veloxity supports peptide and GLP-1 receptor agonist (RA) programs with proven LC–MS/MS methods, low-nM sensitivity and rapid turnaround. Our brochure highlights our experience, selectivity and speed—showing how we deliver reliable, on-schedule results across study phases.

Drug programs can lose weeks to slow bioanalysis, siloed handoffs and documentation gaps. This report shows how to align LC–MS/MS to the next phase from day one—moving seamlessly from discovery through GLP and into clinical. You’ll get practical checklists, “tips & traps,” real-world snapshots and sponsor perspective from our guest co-author, industry veteran, Andy Vick, PhD, BlueWater Biosciences. Ideal for teams aiming to combine speed with scientific rigor under GLP/GCP and ICH M10 expectations.

Veloxity Labs built VELO, a custom LQMS that unifies workflows, speeds timelines, ensures data integrity, and delivers clear client communication. Download our report to learn more.

Download this report to learn how bioanalytical partners can accelerate high-complexity programs with small samples and high stakes.

The newly released 2025 FDA Biomarker Guidance marks a step forward in biomarker bioanalysis regulation. Download our report to learn more.